Opinion|Videos|April 29, 2024
Barriers to Accessing New Anti-Diabetes Medications
Medical experts underscore disparities in diabetes treatment access, stressing the impact of insurance plans on treatment decisions, which can hinder patients and providers, especially when considering newer medications like GLP-1 agonists.
Advertisement
Episodes in this series
Advertisement
Related to this article
These data from CARDIO-TTRansform were presented at HFSA 2026, highlighting positive data from the trial despite its failure to improve cardiovascular mortality.
A propensity-matched TriNetX analysis presented at ACG 2026 found lower MACE and mortality with resmetirom vs semaglutide over 2 years in MASLD/MASH.
Volixibat reduced itch scores vs placebo in patients with PSC and moderate to severe pruritus in the phase 2b VISTAS trial presented at ACG 2026.
Topline phase 3 ALOFT-IPF data show admilparant 60 mg improved 52-week FVC vs placebo in IPF, while the 120 mg dose missed statistical significance.
Post hoc FORTIFY OLE analyses presented at ACG 2026 show sustained remission across disease locations and rising no-draining-fistula rates over 5 years.
Topline data show a 69% placebo-adjusted drop in serum bile acids, with an sNDA planned for the first half of 2027.
Jennifer Hsiao, MD, discusses HS treatment expectations, biologic selection, oral JAK inhibitors, and comorbidity screening.
Phase 3 extension shows oral denifanstat sustains acne lesion reductions through 52 weeks, with 57% IGA success and 77% fewer inflammatory lesions.
Advertisement
Advertisement
Trending on HCPLive
1
ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point
2
Resmetirom Tied to Lower MACE vs Semaglutide in Real-World MASLD Analysis
3
Long-Term Risankizumab Data Show Durable Crohn’s, Fistula Outcomes
4
Eplontersen Fails to Achieve Primary Endpoint, Improves KCCQ and 6MWT in ATTR-CM
5